Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 22Terminated 4Withdrawn 2Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 34Neoplasm Metastasis 7Neoplasms 4Urinary Bladder Neoplasms 3Stomach Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Esophageal Neoplasms 2Carcinoma, Squamous Cell 2Breast Neoplasms, Male 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Skin Neoplasms 1Recurrence 1Prostatic Neoplasms 1Metastatic Breast Cancer With Intracranial Metastases 1Melanoma 1Inflammatory Breast Neoplasms 1Her2 Positive Metastatic Breast Cancer 1Head and Neck Neoplasms 1HER2 Positive Esophagogastric Cancer 1GastroEsophageal Cancer 1Esophageal Squamous Cell Carcinoma 1Diarrhea 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1Carcinoma 1Breast Diseases 1Brain Neoplasms 1

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Lapatinib × Clear all
NCT02294786 2019-07-15

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Novartis

Phase 2 Terminated
62 enrolled 25 charts
Breast

Breast Neoplasms, Diarrhea, Neoplasms

NCT00968968 2019-06-10

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Novartis

Phase 3 Terminated
37 enrolled 11 charts
Tumor-Agnostic

Carcinoma, Neoplasms

NCT00447226 2012-06-12

Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists

GlaxoSmithKline

Phase 2 Terminated
32 enrolled 10 charts
GastrointestinalGenitourinaryGynecologic

Urinary Bladder Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms

NCT00888810 2009-04-28

TOPO-LAPA

Centre Francois Baclesse

Phase 2 Terminated
39 enrolled

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡